Sabag Mark's Form 4 filing
Teva Pharmaceutical Industries LtdTEVA · filed Nov 12, 2026
- Accession no.
- 0001193125-26-458410
- Filed
- Nov 12, 2026, 4:12 PM ET
- Trade date
- Nov 12, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.97M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sabag MarkCIK 0001721442 | Officer (See "Remarks") |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Ordinary Shares | MOption exerciseAcquired | +44,710 | $34.90 | +$1,560,379 | 125,470 | Direct | |
| Nov 12, 2026 | Ordinary Shares | SSaleDisposed | −44,710 | $44.14F1 | −$1,973,544.11 | 80,760 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Ordinary Shares | MOption exerciseDisposed | −44,710 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.10 to $44.29, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Remarks
Executive Vice President, International Markets Commercial